New ETF Book by Larry Connors - Click here to read more
On April 21, the following concurrent sessions will take place under the "Quality Science" track: 8:00 - 8:30 am: A Novel Approach to Addressing Low Level Trends and Non-Zero Results--presented by Robert Lutskus, Supervisor, QC Microbiology Laboratory Systems, ImClone Systems. 8:30 - 9:00 am: Improvement in QC Environmental Monitoring Processes by Implementation of a Paperless Data Capture System--presented by Tim Coleman, Senior Director, QC Testing Services, Lonza Walkersville. "Reporting with the tools provided by MODA-EM has been the key to enable us to fully maximize the paperless solution," explains Robert Lutskus at ImClone Systems. "The wide varieties of reports allow us to trend information that previously was not reconciled easily--and, the reporting package allows for detailed and summary level reporting for all aspects of sampling, testing and other results trending."
Additionally, personal demonstrations of MODA-EM(TM) will be given in Booth 604. At the booth, press and attendees can have direct discussions with ImClone Systems and Lonza Walkersville.
To learn more about PDA's Annual Meeting, visit www.pda.org.
To attend MODA's QC Micro Webinar Series or download past presentations, visit www.modatp.com. About MODA MODA provides a mobile data acquisition platform that enables quality assurance and quality control organizations to automate their regulated manufacturing processes, including pharmaceuticals and consumer products. MODA's flagship software, MODA-EM(TM), is a paperless solution that leverages mobile computing technology and advanced visualization tools for increased operational efficiency, improved quality, and reduced costs. For more information, visit www.modatp.com.
About ImClone Systems ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. For more information, visit www.imclone.com.
About Lonza and Lonza Walkersville Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza Walkersville, Inc (formerly Cambrex BioScience Walkersville, Inc) manufactures products for five distinct business units; Cell Discovery, Molecular Biology, Media, Rapid Testing and Cell Therapy Contract Manufacturing. The products range from research reagents to licensed test kits to regulated parenteral products. For more information, visit www.lonza.com.
About PDA The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its more than 11,000 members worldwide. For more information, visit www.pda.org.
# # #
Read the full story at http://www.prweb.com/releases/2009/04/prweb2329084.htm.
PRWeb.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
